NON-MUSCLE INVASIVE BLADDER CANCER

This study is testing whether a liquid treatment called TARA-002 can safely control high-grade bladder cancer that hasn't spread into the muscle wall. Researchers will give the treatment directly into the bladder of 131 adults and monitor them for up to 5 years to see if it preve…

This study is testing a new treatment called cretostimogene grenadenorepvec for people with high-risk bladder cancer that hasn't responded to standard BCG therapy. The treatment involves putting a modified virus directly into the bladder to try to kill cancer cells. Researchers w…

This study is for people whose early-stage bladder cancer has come back. It compares a new approach—a strong drug wash (chemoablation) directly into the bladder—to the standard surgery (TURBT). The main goal is to see if the drug wash can better prevent the cancer from returning …

This study compares different FDA-approved treatments for bladder cancer that hasn't spread into the muscle wall. It tests a newer gene therapy drug called nadofaragene firadenovec against several standard treatment options. The trial is for adults whose cancer returned after ini…

This study is testing if a new approach can safely help some bladder cancer patients avoid a second surgery. It compares a special imaging-guided surgery to the current standard, which involves two surgeries. The goal is to see if the new method controls the cancer just as well w…

This study is testing a new drug delivery system called TAR-210, which is a small implant placed in the bladder to slowly release a targeted cancer drug. It is being compared to standard liquid chemotherapy placed directly into the bladder. The goal is to see which treatment is b…

This early-stage study is testing a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle but is likely to return. The drug is given directly into the bladder, either by itself or combined with other standard treatments. The main …

This early-stage study is testing a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with a specific type of bladder cancer that hasn't spread into the muscle wall. The drug is delivered directly into the bladder. The main goals are to find a safe dose and see how wel…

This early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for bladder cancer that hasn't spread into the muscle wall. Researchers will inject the drug directly into tumors during a standard bladder procedure to see if it's safe and practical to use. The …

This study is testing a new drug called STM-416, which is applied directly into the bladder during tumor removal surgery. The main goals are to see if the drug is safe and if it can help prevent the cancer from returning. The trial will involve about 75 adults with a specific typ…

This study is testing whether adding an investigational drug called N-803 to the standard BCG treatment works better than BCG alone for non-muscle invasive bladder cancer. It will involve nearly 600 patients who have not recently had BCG treatment. The research aims to see if the…

This early-stage study is testing the safety of a new drug called 2141-V11 for people with non-muscle invasive bladder cancer that hasn't responded to standard BCG therapy and who are not having their bladder surgically removed. Researchers will give the drug directly into the bl…

This early-stage trial is testing a new targeted treatment for bladder cancer that hasn't spread into the muscle layer. The treatment uses tiny particles that carry chemotherapy directly to cancer cells, aiming to kill them while potentially reducing side effects. The study will …

This study is testing a combination of two immunotherapy drugs, durvalumab and monalizumab, for people with early-stage bladder cancer that has not responded well to the standard BCG treatment. The goal is to see if this drug combination can eliminate the cancer and help patients…

This program provides access to an investigational treatment called cretostimogene for people with a specific type of bladder cancer that has not responded to the standard BCG therapy. It is for patients who are not eligible for or refuse surgery to remove their bladder. The trea…

This study is testing if adding a daily pill called bicalutamide to the standard BCG bladder wash treatment can better prevent cancer from returning. It will involve about 160 men with early-stage bladder cancer that hasn't spread into the muscle. Participants will be randomly as…

This study is testing whether urine tests can safely replace some of the invasive scope procedures used to monitor for bladder cancer recurrence. It will compare two different urine tests against the standard frequent scope exams in 240 patients with early-stage bladder cancer. T…

This study is testing whether adding Hydeal Cyst bladder treatments can help reduce urinary symptoms and improve quality of life for people with early-stage bladder cancer. The research involves 200 patients who are already receiving standard bladder cancer treatments (BCG or MMC…

This study aims to understand how mood changes in people with early-stage bladder cancer who are receiving a standard treatment called BCG. Researchers will follow 42 patients, asking them to complete daily mood diaries and questionnaires while collecting blood and urine samples.…